Effects of cholecalciferol vs calcifediol on total and free 25-hydroxyvitamin d and parathyroid hormone

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 4, 2017, Pages 1133-1140

  Shieh, Albert ^a   Ma, Christina ^b   Chun, Rene F ^a   Witzel, Sten ^a   Rafison, Brandon ^a   Contreras, Hannah T M ^a   Wittwer Schegg, Jonas ^c   Swinkels, Leon ^d   Huijs, Tonnie ^d   Hewison, Martin ^e   Adams, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

^d Future Diagnostics   (Netherlands)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIFEDIOL; COLECALCIFEROL; PARATHYROID HORMONE; 25-HYDROXYVITAMIN D; CALCIUM; VITAMIN D;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; FEMALE; MALE; MIDDLE AGED; URINE; YOUNG ADULT;

ADULT; CALCIFEDIOL; CALCIUM; CHOLECALCIFEROL; FEMALE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 85017322771     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-3919     Document Type: Article

References (44)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3): 266-281.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
3. Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, Krueger D, Drezner MK. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J Clin Endocrinol Metab. 2011;96(4):981-988.
4. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D (3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96(3):E447-E452.
5. Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2013;98(11):4339-4345.
6. Glendenning P, Chew GT, Inderjeeth CA, Taranto M, Fraser WD. Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol. Bone. 2013; 56(2):271-275.
7. Shieh A, Chun RF, MaC, Witzel S, Meyer B, Rafison B, Swinkels L, Huijs T, Pepkowitz S, Holmquist B, Hewison M, Adams JS. Effects of high-dose vitamin D2 versus D3 on total and free 25-hydroxyvitamin Dandmarkers of calciumbalance. J Clin Endocrinol Metab. 2016;101(8):3070-3078.
8. Institute of Medicine Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.
9. Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed tomaintain a favorable bisphosphonate response is$33 ng/ml. Osteoporos Int. 2012;23(10):2479-2487.
10. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A. Monthly highdose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med. 2016;176(2): 175-183.
11. Gallagher JC. VitaminDand falls -the dosage conundrum. Nat Rev Endocrinol. 2016;12(11):680-684.
12. Francis RM, PeacockM, Storer JH, Davies AE, Brown WB, Nordin BE. Calcium malabsorption in the elderly: the effect of treatment with oral 25-hydroxyvitamin D3. Eur J Clin Invest. 1983;13(5): 391-396.
13. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitaminDadministration. J Clin Invest. 1979;64(2):655-665.
14. Peacock M, Liu G, Carey M, McClintock R, AmbrosiusW, Hui S, Johnston CC. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab. 2000;85(9):3011-3019.
15. Stamp TC, Haddad JG, Twigg CA. Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D. Lancet. 1977; 1(8026):1341-1343.
16. Bischoff-Ferrari HA, Dawson-Hughes B, Stöcklin E, Sidelnikov E, Willett WC, Edel JO, Stähelin HB, Wolfram S, Jetter A, Schwager J, Henschkowski J, von Eckardstein A, Egli A. Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res. 2012;27(1):160-169.
17. Jetter A, Egli A, Dawson-Hughes B, Staehelin HB, Stoecklin E, Goessl R, Henschkowski J, Bischoff-Ferrari HA. Pharmacokinetics of oral vitamin D(3) and calcifediol. Bone. 2014;59:14-19.
18. Cashman KD, Seamans KM, Lucey AJ, Stöcklin E, Weber P, Kiely M, Hill TR. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am J Clin Nutr. 2012; 95(6):1350-1356.
19. Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 2014;144(Pt A):132-137.
20. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol. 2001;280(4):F562-F573.
21. Aloia JF, Chen DG, Yeh JK, Chen H. Serum vitamin D metabolites and intestinal calcium absorption efficiency in women. Am J Clin Nutr. 2010;92(4):835-840.
22. Rosen CJ, Adams JS, Bikle DD, BlackDM, Demay MB,Manson JE, Murad MH, Kovacs CS. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012;33(3): 456-492.
23. Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG, Liebhaber SA, Cooke NE. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest. 1999;103(2):239-251.
24. Bhan I, Powe CE, Berg AH, Ankers E, Wenger JB, Karumanchi SA, Thadhani RI. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int. 2012;82(1):84-89.
25. Schwartz JB, Kane L, Bikle D. Response of vitaminD concentration to vitamin D3 administration in older adults without sun exposure: a randomized double-blind trial. J Am Geriatr Soc. 2016;64(1): 65-72.
26. Aloia J, Dhaliwal R, Mikhail M, Shieh A, Stolberg A, Ragolia L, Fazzari M, Abrams SA. Free 25(OH)D and calcium absorption, PTH, and markers of bone turnover. J Clin Endocrinol Metab. 2015;100(11):4140-4145.
27. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013; 369(21):1991-2000.
28. Aloia J,Mikhail M, Dhaliwal R, ShiehA,Usera G, Stolberg A, Ragolia L, Islam S. Free 25 (OH) D and the vitamin D paradox in African Americans. J Clin Endocrinol Metab. 2015;100(9):3356-3363.
29. Gallagher JC, Sai A, Templin T II, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med. 2012;156(6):425-437.
30. Hsu SA, Soldo J, Gupta M. Evaluation of two automated immunoassays for 25-OH vitamin D: comparison against LC-MS/MS. J Steroid Biochem Mol Biol. 2013;136:139-145.
31. Nielson C, Jones K, Chun R, Jacobs J, Wang Y, Hewison M, Adams J, Swanson C, Lee C, Vanderschueren D, Pauwels S, Prentice A, Smith R, Shi T, Gao Y, Schepmoes A, Zmuda J, Lapidus J, Cauley J, Bouillon R, Schoenmakers I, Orwoll E. Free 25-hydroxyvitamin D: impact of vitamin D binding protein assays on racial-genotypic associations. J Clin Endocrinol Metab. 2016;101(5):2226-2234.
32. Nielson CM, Jones KS, Bouillon R, Chun RF, Jacobs J, Wang Y, Hewison M, Adams JS, Swanson CM, Lee CG, Vanderschueren D, Pauwels S, Prentice A, Smith RD, Shi T, Gao Y, Zmuda JM, Lapidus J, Cauley JA, Schoenmakers I, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Research Group. Role of assay type in determining free 25-hydroxyvitamin D levels in diverse populations. N Engl J Med. 2016;374(17):1695-1696.
33. Denburg MR, Hoofnagle AN, Sayed S, Gupta J, de Boer IH, Appel LJ, Durazo-Arvizu R, Whitehead K, Feldman HI, Leonard MB; Chronic Renal Insufficiency Cohort study investigators. Comparison of two ELISA methods and mass spectrometry for measurement of vitamin D-binding protein: implications for the assessment of bioavailable vitamin D concentrations across genotypes. J Bone Miner Res. 2016;31(6):1128-1136.
34. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res. 2011;26(7):1609-1616.
35. Jemielita T, Leonard M, Baker J, Sayed S, Zemel B, Shults J, Herskovitz R, Denburg M. Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays. Osteoporos Int. 2015;10:1-10.
36. Schwartz JB, Lai J, Lizaola B, Kane L, Markova S, Weyland P, Terrault NA, Stotland N, Bikle D. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. J Clin Endocrinol Metab. 2014;99(5):1631-1637.
37. Brown EM, Pollak M, Hebert SC. Sensing of extracellular Ca2+ by parathyroid and kidney cells: cloning and characterization of an extracellular Ca(2+)-sensing receptor. Am J Kidney Dis. 1995; 25(3):506-513.
38. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerström G, Westin G. 25-hydroxyvitamin D(3)-1a-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab. 2002;87(6):2967-2972.
39. Ritter CS, Brown AJ. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J Mol Endocrinol. 2011;46(2):63-66.
40. Lundgren S, Carling T, Hjälm G, Juhlin C, Rastad J, Pihlgren U, Rask L, Akerström G, Hellman P. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem. 1997;45(3):383-392.
41. Hollis BW, Wagner CL. Clinical review: the role of the parent compound vitaminDwith respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab. 2013;98(12):4619-4628.
42. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis -2016-Executive Summary. Endocr Pract. 2016;22(9):1111-1118.
43. Gibson CC, Davis CT, Zhu W, Bowman-Kirigin JA, Walker AE, Tai Z, Thomas KR, Donato AJ, Lesniewski LA, Li DY. Dietary vitamin D and its metabolites non-genomically stabilize the endothelium. PLoS One. 2015;10(10):e0140370.
44. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95(2):471-478.